

SUBJECT INDEX

A

- Abnormalities
 - paternal exposures and, 159-63
 - central nervous system, 163
 - chromosomal, 159-60
 - congenital, 159, 162-63
 - oral cleft, 163
 - skeletal, 163
 - sperm, 159
- Abortion
 - spontaneous
 - paternal occupational exposures and, 168-70
 - smoking and, 381
- Abruptio placenta
 - prenatal smoking exposure and, 381
- Acid deposition
 - global change and, 116
- Acquired immunodeficiency syndrome (See AIDS)
- Acyclovir
 - herpes simplex and, 20-21
 - resistant mutants of, 20-21
- AIDS
 - acyclovir-resistant herpes simplex and, 20
 - cytomegalovirus and, 21
 - early epidemiology of, 415, 423-24
 - heterosexual transmission of, 415-16, 451-62
 - intravenous drug users and, 413-44
 - condom use among, 416, 441
 - drug abuse treatment and, 436-39
 - harm-reduction perspective on, 414, 424-44
 - heterosexual and perinatal transmission from, 415-16
 - prevention programs for, 426-41
 - rapid spread among, 416-17
 - syringe exchange programs for, 427, 434-36, 439-40
 - Kaposi's syndrome and, 33-35
 - prevention of, 426-41, 461-62
 - gender-specific, 461-62
 - scabies and, 35
 - sexual transmission of, 415-17, 420, 423, 441, 451-62
- Airbags, 519-20
- Air pollution
 - indoor
 - asthma prevalence and, 503-4

- outdoor
 - asthma prevalence and, 502-3
- Alcohol use
 - culture and, 361-62, 364
 - paternal
 - birth defects and, 171
 - low birthweight and, 170-71
- American Medical Directors Association, 564
- Americans With Disabilities Act (ADA), 296
- Anal intraepithelial neoplasia, 25-26
- Androstenedione aromatization, 1-4, 8
 - estradiol and, 2-4
 - estrone and, 2-3, 8
- Anorectal warts, 24-25
- Arizona Garbage Project
 - University of, 145-46, 148
- Asthma
 - ambulatory care for, 494-95
 - hospitalization for, 495-97
 - intervention strategies for, 508-9
 - prevalence of, 492-94, 498
 - Australia, 494
 - England, 494
 - Finland, 493
 - Sweden, 493
 - United States, 492-94
 - changing patterns of
 - public health implications of, 507-8
 - risk factors for, 491, 501-7
 - access to medical care, 506
 - air pollution, 502-3
 - breast feeding rates, 502
 - pharmacotherapy, 506-7
 - prematurity, 502
 - socioeconomic status, 504-5
 - surveillance, 491-509
 - US morbidity and mortality
 - from, 491-509
 - difficulty of making international comparisons with, 492
 - race and, 498-99
- Atherosclerosis
 - serum total cholesterol and, 95
- Automobile safety, 515-39
 - air bags and, 519-20
 - bicyclists and, 535-37
 - consumer interest in, 517, 537-38
 - future of, 530-35
 - motorcyclists and, 535-37
 - pedestrians and, 535-36
 - research on
 - neglect of, 517, 537
 - safety belts and
 - campaign to increase use of, 525-28

- mandatory use laws for, 519-20
 - rates of voluntary use of, 519
 - (See also Traffic injuries)
- ## B
- Bacteriology
 - public health laboratory and future of, 649-63
 - history of, 637-46
 - Baucus amendment, 271, 279
 - Berkson error model, 71-72, 75
 - Biased selection, 246
 - Biodiversity, 116, 124-25, 129
 - extinction and, 116
 - Biodiversity Treaty, 129
 - Birth defects
 - paternal environmental exposures and, 169, 171, 175-76
 - Breast cancer, 1, 3-14, 605-30
 - diet and, 1, 4-14
 - plasma hormone levels and, 1, 4-14
 - screening for
 - cost effectiveness of, 623-29
 - effectiveness of, 606-8, 618-23
 - guidelines for, 608-9
 - mammography, 605-30
 - utilization of, 609-15
 - statistics for, 605-6, 618-22
 - incidence, 618-21
 - mortality, 618
 - stage at diagnosis, 621-22
 - Breastfeeding
 - trends in
 - asthma prevalence and, 502
 - Britain
 - dietary fat consumption in
 - breast cancer incidence and, 4-5
- ## C
- Canadian Global Change Program, 129
 - Cancer
 - breast, 1, 3-14
 - diet and plasma hormone levels and, 1, 3-14
 - elevated 16 α -hydroxylation of estradiol and, 4, 13
 - mammography screening for, 605-30
 - protective role of fiber in, 10
 - cervical
 - intravenous drug users and, 418, 420

- childhood
 paternal occupational exposures and, 159-50, 171-73
 survivors of, 173
 endometrial, 1-4
 obesity-associated, 1-2
 ethnic group differences in incidence of, 360-61
 liver, 100
 low-serum total cholesterol and, 96-102
 Honolulu Heart Program findings on, 100
 International Collaborative Group study on, 96-97
 Multiple Risk Factor Intervention Trial (MRFIT) Screening Follow-up Study findings on, 98-100
 lung, 97, 100
 lymphatic system, 100
 ovarian, 1, 14
 poverty and, 358-61
 prostate, 1, 4, 14
 socioeconomic status and, 358-61
 Cancer risk
 dietary fat and, 1-5
 menopause and, 5
 dietary fiber and, 7-10
 estrogens and, 1-14
 postmenopausal women and, 1-14
 obesity and, 1-2
 vegetarian diets and, 5-8
 Candidiasis
 vaginal
 intravenous drug users and, 418, 420
 vulvovaginal, 33
 Carbon monoxide monitoring
 smoking cessation intervention and, 397, 404
 Carcinogenesis
 sentinel species, 208
 Cardiac arrest
 chain of survival concept and, 313, 317-28
 emergency medical services and, 313-28
 practice pattern of, 315
 enhanced 911 and, 319
 out-of-hospital, 313-28
 sudden cardiac death from, 313
 Cardiopulmonary resuscitation (CPR), 313, 319-22
 citizen initiators of
 out-of-hospital cardiac arrest and, 319
 citizen training for, 321
 ventricular fibrillation and, 320
 ventricular fibrillation/ventricular tachycardia and, 320-21
 (See also Emergency medical services)
 Cardiovascular disease
 expense in US from, 314
 myocardial infarctions
 emergency medical services for, 313-28
 out-of-hospital, 313-28
 (See also Cardiac arrest, Ischemic heart disease, Myocardial infarction)
 Categorical exposure variables, 74-75, 79
 Cervical intraepithelial neoplasia (CIN), 24-26
 rates among HIV-infected women, 24-26
 Cervical warts
 HIV and, 24-25
 Cesarean section
 rates of
 insurance status and, 263
 Chancroid
 HIV and, 30-31, 36, 458-59
 epidemiologic synergy with, 30-31, 36, 458-59
 prostitution and, 30
 resistance to treatment of HIV and, 31
 substance abuse and, 30
 China
 dietary fat consumption in breast cancer incidence and, 4-5
 Chlamydia
 HIV and, 30, 32, 36, 459
 Chlorine monoxide, 117-18
 Chlorofluorocarbons (CFCs), 117-18, 122
 public policy regarding, 122
 Cholesterol
 cell function and, 103-8
 high-density lipoprotein, 103
 smoking and, 103
 high serum total
 coronary heart disease and, 95-96, 98-100
 Honolulu Heart Program findings on, 100, 108
 immune function and, 104
 low-density lipoprotein, 95-96, 98
 low serum total
 cancer mortality and, 96-102
 Conference on Low Cholesterol: Disease Association, 96, 99-100, 108
 disease risk factors that lower, 103-8
 epidemiologic confounding and, 102-3
 excess noncardiovascular mortality and, 95-109
 hemorrhagic stroke and, 97-109
 meta-analyses of clinical trials, 100-2
 public health policy on, 108-9
 MRFIT Screening Follow-up Study findings on, 97-100
 synthesis of, 105-6
 Cholestyramine
 reduced total serum cholesterol and
 coronary heart disease and, 95
 Chronic disease
 Americans With Disabilities Act (ADA) and, 296
 costs of, 293-308
 labor market status and, 293
 Chronic obstructive pulmonary disease
 low serum total cholesterol and, 100
 Cirrhosis of the liver
 low serum total cholesterol and, 100
 Classical error model, 71-72, 75
 Climate change (See Global change, Global warming, Greenhouse effect)
 Clofibrate, 101
 Clustered data
 generalized estimating equations and, 51, 60-64
 generalized linear models and, 43, 46, 51-52, 55-58, 66
 marginal models, 55-56
 Markov model, 58-60, 62
 odds ratio and, 51, 54-56, 64-65
 random effects models and, 56-58, 61
 transition models, 58-60, 62
 unified statistical method, 45, 55-62
 Continuous exposure variables, 76, 80-85
 distribution of true exposure and, 83-84
 full likelihood and, 82-83
 modeling exposure and, 84-85
 regression coefficients and, 80-81
 structural equations and, 81-82
 Coronary heart disease
 Helsinki Heart Study on, 95
 Honolulu Heart Program on, 100, 108
 low-density lipoproteins and, 95-96, 98
 Multiple Risk Factor Intervention Trial (MRFIT) Screening Follow-up Study on, 97-100
 serum total cholesterol and, 95-102
 meta-analysis of clinical trials on, 100-2
 Cost containment
 practice guidelines and, 226-29, 232-39
 volume of services and, 223-27, 233-39
 Cotinine, 404-5
 Cow's milk
 equol in, 10-12

- Cultural diversity
 cancer incidence and, 360-61
 disease incidence and mortality and, 260-61
 health knowledge, attitudes, and behavior and, 363-66
 AIDS, 364
 lead exposure, 365-66
 smoking, 363-64
 health promotion and, 360-75
 health status and, 355-58, 360-66
 risk factor exposure and, 361-63
 alcohol use, 361-62
 diet, 362-63
 smoking, 361, 363
 (See also Ethnicity, Race, Socioeconomic status)
- Cyclophosphamide
 male-mediated effects on offspring and exposure to, 163, 168, 174-75
- Cyclosporine, 103
- Cytomegalovirus
 AIDS patients and, 21
 effects of HIV infection on, 21
 epidemiologic synergy with HIV and, 21-22
 progressive retinitis and, 21-22
 ganciclovir treatment for, 22
- D
- Databases
 sentinel health events and, 209
- Decision making
 risk perception and, 183-200
 design of risk communications and, 196-200
- Decision rules
 surveillance of sentinel health events and, 210-11
- Defibrillation
 cardiac arrest and, 313-17, 322-26
 home programs for high-risk patients and community responders, 324-26
- Disability
 work effort and, 293-308
- Developing countries
 spread of HIV in intravenous drug users and, 420-23
- Developmental outcomes
 paternal exposures and adverse, 159-77
 animal data on, 160-68
 cancer, 159-60, 171-73
 central nervous system abnormalities, 163
 chromosomal abnormalities, 159-60
 epidemiologic findings on, 168-74
 gene mutation, 159-68
 growth retardation, 160
 neurobehavioral effects, 160, 163, 168
 potential mechanisms of, 174-76
 spontaneous abortion, 159, 168-70
 tumors, 160, 163, 171-73, 175
- Developmental toxicity
 male-mediated, 159-77
 potential mechanisms of, 174-76
 (See also Developmental outcomes)
- Diet
 cancer and, 1-14, 86-87, 90
 fat and, 1-5
 fiber and, 7-10
 cancer risk and wheat bran and, 9
 international comparisons of, 4-13
 plasma hormone levels and, 4-13
 low-fat/high-fiber, 8-10
 macrobiotic, 12
 radiation exposure and, 74
 vegetarian, 5-8
- Disease control
 surveillance of sentinel health events and, 205-15
- Disposal
 sewage, 137
 solid waste, 139-57
 (See also Municipal solid waste)
- Disposal sites
 Environmental Protection Agency (EPA) rules governing, 141
 historical perspective on, 137-42
 landfills, 140, 142, 146, 149-52
 ocean, 139, 142, 149
 (See also Municipal solid waste)
- Dominant cataract test
 mammalian germ cell mutagenicity and, 162-63
- Dominant lethal test
 mammalian germ cell mutagenicity and, 161-62
- Dominant skeletal test
 mammalian germ cell mutagenicity and, 162-63
- Dose-response relationship, 69, 74, 78
 linear, 78
 residual confounding, 78
 spurious interaction and, 78
- Dosimetry, 86, 89-90
- Drug-abuse treatment
 HIV transmission reduction and, 427, 434-36, 439-40
 harm reduction perspective and, 427, 434-36, 439-40
- E
- Early advanced cardiac life support link, 326-27
- Early and Periodic Screening, Diagnosis and Treatment Program, 257-58
- Economic incentives
 controlling volume of services and, 224-26
 practice guidelines
 improving quality of care through, 236-38
- Elderly
 characteristics of privately insured, 275-76
 health insurance among, 271-91
 Baucus amendment and, 271, 279
 duplicate coverages of, 278-80
 employer-sponsored, 271, 274, 278, 280-87
 health maintenance organization (HMO), 273
 hospital indemnity, 273
 major medical, 273-75
 Medicare, 271-91
 medigap, 271-91
 nursing home, 273
 use of restraints on change in US social philosophy regarding, 545
 chemical restraints and, 567-68, 576-79
 dangers of, 547-48, 557, 566
 nursing homes and, 545-81
 Omnibus Budget Reconciliation Act (OBRA 1987) nursing home reform and, 547-49, 560-62, 564, 576
 patients' rights and, 548
 professional dominance versus patient autonomy, 545-46, 548, 558
 quality of life and, 547
 (See also Nursing homes, Restraints, Omnibus Budget Reconciliation Act 1987)
- Emergency medical services
 chain of survival of, 313, 317-28
 cardiopulmonary resuscitation, 313-27
 defibrillation, 313-17, 322
 early access, 318-19
 intravenous medications, 313, 326-28
 intubation, 313, 326-28
 enhanced 911, 319, 327-28
 out-of-hospital cardiac arrest and, 313-28
 practice patterns of, 315-17
 US Department of Transportation guidelines and, 314
 (See also Cardiac arrest, Cardiopulmonary resuscitation)
- Employer-sponsored post-retirement insurance, 271, 274, 278, 280-87, 290
 coverage, 282-83, 284-85
 changes in, 284-85

- people covered by, 280-81
 people promised coverage by, 281
 prefunding, 285-87
 relation to Medicare, 280, 283-84
Endocarditis, 413, 418
 Environmental contamination, 115-22
 aquatic ecosystems, 116
 global change and, 115-22
 ozone depletion and, 115-22
 pesticides and, 115
 toxic chemicals and, 115-16
 Environmental ethics, 115, 128-29, 131-32
 Environmental Protection Agency (EPA) Gene-Tox Program, 162
 Environmental Protection Agency—International Agency for Research on Cancer (EPA-IARC) Genetic Activity Computer Program, 162
Escherichia coli outbreaks
 public health laboratories and, 652
 Estradiol, 2-14
 breast cancer risk and, 2-14
 elevated 16 α -hydroxylation of, 4, 10, 13
 testosterone and, 8
 Estrogens
 blood, 1-14
 aromatization of androstenedione and, 1-2, 13
 cancer risk and, 1-14
 dietary fiber and, 8-10
 glucuronides and, 3
 sulfoglucuronides and, 3
 Estrone, 2-3, 8
 Ethnicity
 cancer morbidity and mortality and, 362
 cardiovascular disease patterns and, 362
 dietary intake and, 362-63
 health promotion and, 360-75
 poverty and, 356-58
 (See also Cultural diversity)
 Ethylnitrosourea (ENU), 162-63
 paternal exposure to
 adverse developmental outcomes and, 162-63
 Equol, 10-12
 Soya and, 11
 Exposure measurement error
 analytic studies and, 88-90
 Berkson error model, 71-72, 75
 classical error model, 71-72, 75
 correction of
 categorical exposure variables and, 79
 continuous exposure variables and, 80-85
 distribution of, 72-74
 pathway uncertainty analysis and, 73
 reproducibility studies of, 73
 validation studies of, 73
 Ecologic studies and, 88-90
 effects of
 categorical exposure variables and, 74-75, 79
 continuous exposure variables and, 76, 80-85
 variance structures and, 76-77
 regulatory policy and, 90
 sample size and, 87-88
F
 Fat
 dietary
 breast cancer incidence and, 4-14
 plasma estradiol and estrone levels and, 4-5
 prostate cancer incidence and, 4, 14
 sex hormone-binding globulin levels and, 5
 Fetal loss
 paternal environmental exposures and, 168-70
 Fiber
 dietary
 breast cancer risk and, 7-10
 Finland
 diet and cancer incidence in, 6, 11-12
 Foscarnet
 mucocutaneous acyclovir-resistant herpes virus and, 21
 Framingham study, 78
G
 Gamma regression model, 53
 Ganciclovir
 cytomegalovirus and, 22
 Garbage (See Municipal solid waste)
 Garbage Project
 University of Arizona, 145-46, 148
 (See also Municipal solid waste)
 Gene mutation, 159-68
 animal data on, 160-68
 paternal exposure and, 159-68
 possible mechanisms of male germ-cell, 174-76
 Generalized estimating equation, 51, 60-64
 Generalized linear models, 43, 46, 51-52, 55-58, 66
 Genital ulcer disease, 19, 30-31
 chancroid, 30-31
 donovanosis, 30
 epidemiologic synergy with HIV, 30-31, 458-59
 lymphogranuloma venereum and, 30
 Genital warts
 HIV and, 24-25
 Geographic Information Systems (GIS), 209
 Geometric standard deviation, 83-84
 Geriatrics
 rise of
 trend away from use of restraints and, 546
 Germ cell mutagens
 paternal exposure and
 animal data on, 160-68
 Germ cells
 direct genetic effects on male, 160-68, 174-76
 animal data on, 160-68
 dominant lethal test for, 161-62
 epidemiologic findings on, 168-74
 heritable translocation test for, 161-62
 potential mechanisms of, 174-76
 specific locus test for, 160-61
 Global change
 acid deposition and, 116
 Biodiversity Treaty and, 129
 Canadian Global Change Program, 129
 components of, 115-16
 ecosystem variation and, 116
 environmental pollution, 115-16
 Global Climate Observing System, 128
 greenhouse warming, 115-16, 122-28
 ozone depletion and, 115-22
 population growth, 115-16
 research needs, 121-22
 resource depletion and, 116
 public health response to, 129-31
 United Nations Conference on Environment and Development (UNCED) and, 128-29
 Global Climate Observing System, 128
 Global warming, 115-16, 122-31
 food supplies and, 124-26
 health effects of, 126-28
 public health response to, 129-31
 sea level rise with, 125-26
 vector-borne diseases and, 126
 weather and, 124
 (See also Global change, Greenhouse effect, Greenhouse gases, Ozone depletion)
 Gonorrhea
 effect of HIV on, 32, 36
 HIV and, 459
 Greenhouse effect
 global warming and, 115-16, 122-28
 sea level rise with, 125-26
 temperature trends and, 123
 weather and, 124
 Greenhouse gases, 122-28
 temperature trends and, 123

- Groundwater contamination
 - municipal solid wastes and, 140-41, 148, 150
 - Growth retardation
 - paternal exposures and, 160, 163
 - H
 - Harm reduction, 414, 424-44
 - basic premise of, 424-25
 - distribution of bleach for, 439
 - drug users' organizations and, 438-39
 - early drug prevention programs and, 439-40
 - increased drug abuse treatment and, 436-39
 - intravenous drug users and, 414, 424-44
 - stigmatization of, 426
 - multiple solutions for, 425
 - over-the-counter sale of sterile injection equipment for, 434-36
 - risk reduction or risk elimination?, 439-40
 - syringe exchange for, 427, 434-36, 439-40
 - Harvard Six Cities study, 89
 - Hawaii
 - dietary fat consumption in
 - estrene concentrations and, 5
 - plasma estradiol concentrations and, 5
 - Hazardous waste
 - household, 149, 155
 - Health behavior
 - risk perception and, 183-200
 - design of risk communications and, 196-200
 - Health care expenditures
 - controlling volume of services and, 223-27, 233-39
 - financial incentives for, 224-26
 - practice guidelines and, 233-39
 - requirements for maintaining quality while, 226-27
 - utilization review for, 224-26
 - cost containment and, 223-29, 232-39
 - hospital costs
 - historic rate of increase of, 223
 - improving quality of care and practice guidelines and, 232-39
 - 1992 estimates in US for, 220
 - physicians' services and, 220-21
 - practice patterns and, 226-32
 - 2020 projections in US for, 220
- Health insurance
 - retiree
 - duplicate coverages of, 278
 - employee-sponsored, 271, 274, 278, 280-87
 - health maintenance organization (HMO), 273
 - hospital indemnity, 273
 - individually purchased, 271
 - major medical, 273-75
 - Medicaid, 273, 275-76
 - Medicare, 271-90
 - medigap, 271-90
 - nursing home, 273
 - specific disease, 273
 - supplemental, 271-90
 - increased Medicare expenditures and, 287-90
 - volume of service use and, 287-89
 - universal, 243
- Health insurance access
 - use of health services and, 243-63
- ambulatory visits, 250-53
- cesarean section rates, 263
- health outcomes and, 263-64
- hospital care, 260-63
- inequity of care based on, 264-60
- length of hospital stay, 261-62
- life-saving therapies from hospitals, 262
- location of care, 249
- prenatal care, 258-59
- prescription drug use, 258
- preventive care, 257-58
- public hospital use, 250
- quality of hospital care, 263
- timeliness, 254, 257
- usual source of care, 247
- Health-labor market status relationship, 293-308
 - analytic approach to, 296-99
 - empirical evidence of, 299-306
 - first-generation research results, 300-3
 - second-generation research results, 304-6
- Health maintenance organizations (HMOs)
 - compared with fee-for-service practice, 222
 - profiling of, 226
- Health promotion
 - cultural diversity and, 360-75
 - health care system and, 370-73
 - intervention channels for, 366-70
 - poverty and, 358-60, 373-75
- Health research, 472-75, 480-82
 - biomedical, 473
 - clinical, 473
 - epidemiologic, 473-74
 - health systems, 473
 - mission-oriented, 481-82
 - public health, 473
- Health service access
 - health insurance status and, 243-63
 - ambulatory visits, 250-53
 - cesarean section rates and, 263
 - health outcomes and, 263-64
 - hospital care, 260-63
 - inequity of care based on, 264-66
 - length of hospital stay, 261-62
 - life-saving therapies from hospitals, 262
 - location of care, 249
 - prenatal care, 258-59
 - prescription drug use, 258
 - preventive care, 257-58
 - public hospital use and, 250
 - quality of hospital care and, 263
 - timeliness, 254, 257
 - usual source of care and, 247-49
- Health services delivery
 - health systems and comprehensive, 336, 344-47
 - entrepreneurial, 336-40
 - socialist, 336, 347-51
 - welfare-oriented, 336, 340-44
- Health service management
 - health systems and comprehensive, 336, 344-47
 - entrepreneurial, 336-40
 - socialist, 336, 347-51
 - welfare-oriented, 336, 340-44
- Health status, 245
- Health status measurement
 - chronic health impairments and
 - labor market status and, 293-308
- Health systems
 - components of
 - delivery of services, 335-36
 - economic support, 335-36
 - management, 335-36
 - organization, 335
 - resources, 335
 - comprehensive, 336, 344-47
 - Costa Rica, 346
 - Great Britain, 344, 352
 - Greece, 345
 - Norway, 344-46
 - Spain, 345
 - Sri Lanka, 346-47
 - Sweden, 344-46, 352
 - entrepreneurial, 336-40
 - Kenya, 339-40
 - Philippine Republic, 338-39
 - United States, 336-38
 - international comparison of, 335-53
 - socialist, 336, 347-51
 - Cuba, 348-49
 - People's Republic of China, 349-51, 353
 - Soviet Union (former), 347-48, 353

- welfare-oriented, 336, 340-44
 Australia, 340
 Austria, 341
 Belgium, 341
 Canada, 340-41
 Germany, 340-41
 India, 343-44
 Japan, 340
 the Netherlands, 341
 Peru, 341-43
- Helsinki Heart Study
 total serum cholesterol lowering and, 95, 101
- Hemolytic uremia syndrome, 652
- Hemophilus ducreyi*, 30-31
- Hemorrhagic stroke
 epidemiologic correlates of, 97-100
- Honolulu Heart Study findings regarding, 100
- hypertension and, 98
- low serum total cholesterol and, 97-109
- epidemiologic confounding and, 102-3
- Multiple Risk Factor Intervention Trial (MRFIT)
 Screening Follow-up Study results and, 97-100
- persons susceptible to, 106-7
- Hepatitis B
 effect of HIV on
 decreased responsiveness to hepatitis B vaccine, 22
 α -interferon therapy and, 23
- epidemiologic synergy with HIV, 22-24, 36
- intravenous drug users and, 23-24, 413
- perinatal and childhood transmission of, 22
- rates of infection of adolescents in high risk settings, 24
- heterosexual, 23-24
- homosexual men, 23
- intravenous drug users, 23-24, 413
- sexually transmitted, 22-24
- Heritable translocation test
 mammalian germ cell mutagenicity and, 161-62
- Herpes simplex
 acyclovir-resistant
 foscarnet treatment of, 20-21
- thymidine kinase-deficient, 20
- HIV infection and, 19-21, 36
- homosexual men with AIDS and, 20
- Herpes simplex type 2
 genital
 HIV and, 458-59
- Highway safety (See Automobile safety)
- HIV
 epidemiologic synergy with other sexually transmitted diseases, 19-36, 457-59
- candidiasis, 33
- chancroid, 30-31, 36
- chlamydia, 32
- cytomegalovirus, 21-22
- genital ulcer disease, 30-31
- gonorrhea, 32
- hepatitis B, 22-24
- herpes simplex, 19-21
- human papillomavirus infection, 24-26
- Kaposi's sarcoma, 33-35
- molluscum contagiosum, 26-27
- pelvic inflammatory disease, 32-33, 418, 420
- scabies, 35
- syphilis, 27-30
- vaginitis, 33
- vaginosis, 33
- epidemiology of, 415, 423-24
- heterosexual transmission of, 415-16, 451-62
- gender differences in, 451-52, 454-57, 462
- interaction with other sexually transmitted diseases, 19-36, 457-59
- intravenous drug users and, 415-16, 451
- properties of, 453-54
- risk factors for, 454-59
- sexual practices and, 454-57, 459
- socioeconomic factors of, 460
- intravenous drug users and, 413-44
- developing countries and, 420-23
- harm reduction perspective and, 414, 424-44
- heterosexual transmission from, 415-16, 451
- perinatal transmission from, 415-16
- prevention programs for, 426-40
- rapid spread among, 416-17
- prevention of
 gender-specific, 461-62
- sexual transmission of, 415-17, 420, 423, 441, 451-62
- Homozygous α -beta-lipoproteinemia, 105-6
- Honolulu Heart Program, 87, 100, 108
- risk for hemorrhagic stroke and
 low serum total cholesterol and, 100, 108
- Human immunodeficiency virus (See HIV)
- Human papillomavirus (HPV) infection
 anal intraepithelial neoplasia and, 25-26
- cervical cancer and, 24-26
- epidemiologic synergy with HIV, 24-26, 459
- 17-Hydroxysteroid dehydrogenase, 2
- I
- Immunosuppression, 119-20
- UV radiation and, 119-20
- Injuries
 traffic (See Traffic injuries)
- Intelligent vehicle and highway system (IVHS) technology, 530, 534
- Ischemic heart disease
 cardiac arrest due to
 out-of-hospital, 313-28
- expense in US from, 313-14
- mortality rate in US from, 314 (See also Cardiac arrest, Cardiovascular disease, Myocardial infarction)
- Intrauterine growth retardation
 prenatal exposure to smoking and, 381-82
- Intravenous drug users, 413-44
- endocarditis among, 413, 418
- harm reduction and, 414, 424-44
- hepatitis B and, 413, 434
- HIV/AIDS and, 413-44
- developing countries and, 420-23
- heterosexual transmission of, 415-16
- perinatal transmission of, 415-16
- prevention programs for, 426-42
- HIV-related non-AIDS infections among
 bacterial pneumonia, 418, 423
- cervical cancer, 418, 420
- endocarditis, 413, 418
- pelvic inflammatory disease, 418, 420
- tuberculosis, 418-20
- vaginal candidiasis, 418, 420
- sexual transmission of disease among, 415-17, 420, 423, 441
- J
- Japan
 dietary fat consumption in breast cancer incidence and, 4-5
- Judgment
 risk perception and, 183-200
- design of risk communications and, 196-200
- K
- Kaposi's sarcoma, 29, 33-35
- anal oral contact and, 34
- epidemiologic synergy with HIV, 33-35
- L
- Landfills, 140, 142, 146, 149-52
- excess packaging of consumer goods and, 141, 146-47

- Japan, 151
- low rate of biodegradability
 - in, 146
 - position in Waste Hierarchy, 142
 (See also Municipal solid waste)
- Lead
 - exposure to socioeconomic status and, 365-66
- Leukemia
 - childhood
 - electromagnetic fields and, 84
 - paternal occupational exposures and, 171-73
 - Utah fallout studies of, 83-84
 - Lipid Research Clinics Coronary Primary Prevention Trial, 95
- Lipoproteins
 - apoprotein B-containing, 106
 - high-density, 103
 - low-density, 95-96
- Lovastatin, 101, 106
- Low birthweight
 - paternal environmental exposures and, 170-71
 - prenatal smoking exposure and, 379-82
 - intrauterine growth retardation and, 381-82
 - preterm delivery and, 382
- Low-density lipoprotein cholesterol
 - coronary heart disease and, 95-96, 98
- Lymphoma
 - paternal occupational exposure and, 172
- M
- Maine Medical Assessment Foundation, 224
- Malignant melanoma
 - UV radiation and ozone depletion and, 119-21
- Mammography, 605-30
 - clinical breast examination with, 606
 - effectiveness of, 606-8, 618-23
 - cost-effectiveness of, 623-29
 - guidelines for, 608-9
 - stage of cancer at diagnosis, 621-22
 - race and, 622
 - trends in breast cancer incidence and, 618-21
 - trends in breast cancer mortality and, 618
 - trends in rate of advanced breast cancer, 622
 - utilization, 609-15
- Marginal models, 55-56
- Market intervention
 - health systems and comprehensive, 336, 344-47
 - entrepreneurial, 336-40
- socialist, 336, 347-51
- welfare-oriented, 336, 340-44
- Markov model, 58-60, 62
- Medicaid
 - biased selection and, 346
 - elderly and, 273, 275-76
 - health outcomes and, 264
 - health status and, 246
 - hospital care, 260-63
 - length of hospital stay, 261-62
 - loss of, 249
 - patient characteristics, 246-47
 - prenatal care, 258-59
 - prescription drug use and, 258
 - preventive care, 257-58
 - Early and Periodic Screening, Diagnosis and Treatment program, 257-58
 - quality of hospital care, 265
- Medicare
 - Medicare Fee Schedule, 222-23
 - Medicare Volume Performance Standard, 225
 - profiling rates, 227
 - program, 272-73
 - ambulatory care; Part B, 273
 - in-patient care; Part A, 272-73
 - proposal to raise the age of coverage by, 295
 - supplemental insurance and, 271-91
 - health maintenance organization (HMO), 273
 - hospital indemnity, 273
 - increased Medicare expenditures and, 287-90
 - major medical, 273-75
 - Medicaid, 273, 275-76
 - medigap, 271-91
 - nursing home, 273
 - utilization review, 225
 - volume of services, 223
- Medicare Catastrophic Coverage Act, 271
- Medicare Fee Schedule, 273
- Medicare Volume Performance Standard, 225
- Medigap insurance, 271-80, 283
 - consumer information about, 278-80
 - covered services, 276, 278
 - federal legislation regarding, 278-80
 - increased Medicare expenditures and, 287-90
 - why consumers buy, 278
- Menopause
 - breast cancer risk and prognosis in
 - diet and, 1-14
- Metered dose inhalers, 506-7
- Mevalonic aciduria, 106
- Molluscum contagiosum
 - AIDS and, 26-27
 - epidemiologic synergy with HIV, 26-27
- Montreal protocol, 122
- Mothers Against Drunk Driving (MADD), 521, 524
- Motor vehicle safety (See Automobile safety)
- Multiple Risk Factor Intervention Trial (MRFIT) Screening Follow-up Study, 97-100
 - hemorrhagic stroke and, 97-100
 - low serum cholesterol and, 98-100
- Municipal solid waste, 137-57
 - collection of, 139, 142-43, 153
 - components of, 142-49
 - food wastes, 148
 - household hazardous, 149
 - metals, 147
 - miscellaneous, 148-49
 - plastics, 147-48
 - tires, 148-49
 - yard waste, 147
 - disposal of, 139-57
 - city dump, 140
 - Environmental Protection Agency (EPA) rules governing, 141
 - landfill, 140, 142, 146, 149-52
 - incineration, 139
 - ocean dumping, 139, 142, 149
 - groundwater contamination from, 140-41, 148, 150
 - source separation of, 138-39, 142, 153-54
- University of Arizona Garbage Project, 146-46, 148
- Waste Hierarchy of, 141-42, 149-56
 - burning for energy, 141, 152
 - combustion, 141, 146, 148, 152-53
 - composting, 141, 147-48
 - landfilling, 140, 142, 146, 149-52
 - reconsidered, 149-56
 - recycling, 141-42
 - source reduction, 141, 146-47, 155-56
- Mutagens
 - male germ cell
 - detection of, 160-68
 - mammalian germ cell assay results, 164-67
- Mutation
 - male-mediated developmental toxicity and, 159-68, 174-76
 - animal data on, 160-68
 - dominant lethal test for, 161-62
 - heritable translocation test, for, 161-62
 - potential mechanisms of, 174-76
 - radiation and, 160, 162-63, 168, 172-73

- specific locus test for, 160-62
- Mycobacterium tuberculosis*, 28
- Myocardial infarction mortality rate in US from, 313-14
- serum cholesterol level and, 100-1
- (See also Cardiac arrest, Cardiovascular disease)
- N**
- Nader, Ralph, 517, 519
- National Citizens Coalition for Nursing Home Reform (NCCNHR), 547-48
- Nursing homes
- poor quality care in
- excessive use of psychoactive drugs and, 568
- use of restraints of elderly in, 545-81
- change of US social philosophy regarding, 545
- dangers of, 547-48, 557, 566
- Institute of Medicine report on, 549, 559-60
- Omnibus Budget Reconciliation Act (OBRA) of 1987 and, 547-49, 560-62, 564, 568, 576-79
- patients' rights and, 548
- professional dominance: versus patient autonomy and, 545-46, 548, 558
- (See also Elderly, Psychoactive drugs, Restraints)
- O**
- Obesity
- breast cancer risk and, 1-14
- plasma estrone sulfate concentrations and, 3-4
- postmenopausal women and, 1-14
- premenopausal women and, 8
- endometrial cancer and, 1-2
- increased androstenedione aromatization rates and, 2
- increased plasma estrogen levels and, 2
- Occupational exposure
- paternal
- birth defects and, 171
- childhood cancer and, 171-73
- fetal loss and, 168-70
- low birthweight and, 170-71
- prematurity and, 170-71
- sentinel health events and, 208-9
- (See also Developmental outcomes, Paternal exposures)
- Ocean Dumping Act of 1972, 139
- Odds ratio, 51, 54-56, 64-65, 70, 75, 78-79
- Omnibus Budget Reconciliation Act (OBRA)
- 1981, 254
- 1990, 272, 280, 290
- 1987
- Nursing Home Reform
- Amendments of, 547-49, 560-62, 564, 576
- use of psychoactive drugs and, 568, 576-79
- use of restraints and, 547-49, 560-62, 564, 576
- Outcomes
- health care access and
- health insurance access and, 263-64, 264-66
- Outcomes research, 226-27, 230
- Ozone depletion, 115-32
- chlorine monoxide and, 117-18
- chlorofluorocarbons and, 117
- public health response to, 121-22, 129-31
- public policy and, 122
- research needs regarding, 121
- trend assessment and, 120-21
- ultraviolet radiation and, 117-20
- effects on phytoplankton of, 118-19
- greenhouse effect and, 119
- human health effects of, 118-20
- P**
- Paternal environmental exposures
- adverse developmental outcomes from, 159-77
- animal data on, 160-68
- cancer among offspring, 159-60, 171-73
- central nervous system abnormalities, 163
- chromosomal abnormalities, 159-60
- epidemiologic findings on, 168-74
- gene mutation and, 159-68
- growth retardation, 160
- neurobehavioral effects, 160, 163, 168
- potential mechanisms of, 174-76
- Pathway uncertainty analysis, 73
- Pelvic inflammatory disease
- effect of HIV on, 32-33
- intravenous drug users and, 418, 420
- Pharmaceutical industry
- Chinese, 350
- German, 340-41
- Physician practice guidelines (See Practice guidelines)
- Physician practice patterns (See Practice patterns)
- Phytoestrogens, 10-12
- equol, 10-12
- Placenta previa
- prenatal smoking exposure and, 381
- Poisson regression model, 53
- Population dynamics, 115-16, 130-32
- armed conflicts and, 116
- global change and, 115-16, 130-31
- migration and, 130
- municipal solid waste and, 137-42
- population growth and, 131-32
- Population health trends
- early retirement and, 295-308
- Poverty
- ethnicity and, 356-58
- health promotion and, 358-60, 373-75
- health status and, 355-60
- political perspective of, 358
- race and, 356-58
- US rate of, 356
- Practice guidelines, 226-29, 232-37
- delivery of services and, 234
- elements of, 233-34
- identifying appropriate cost-effective care via, 232-36
- improving practice through, 236-37
- profiling physicians' performance and, 232
- utilization review and
- appropriate care and, 232-33
- Pregnancy
- smoking during, 379-407
- abruptio placenta and, 381
- bleeding and, 381
- intervention trials to quit, 388-407
- intrauterine growth retardation and, 381-82
- low birthweight and, 379-82
- placenta previa and, 381
- spontaneous abortion and, 381
- Prematurity
- asthma and, 502
- paternal environmental exposures and, 170-71
- Prenatal care
- health insurance status and, 258-59
- Prenatal exposure
- cigarette smoke
- abruptio placenta and, 381
- bleeding during pregnancy and, 381
- intrauterine growth retardation and, 381-82
- low birthweight and, 379-82
- placenta previa, 381
- spontaneous abortion, 381
- paternal environmental exposures and, 159-77
- smoking cessation intervention trials and, 388-407

Preventive care
 insurance status and, 257-58
 Profiling
 improving quality of, 229-31
 physician practice pattern,
 227-32
 assessment of performance
 and, 228-32
 quality improvement and,
 228-32, 238-39
 utilization review and, 228-
 29
 Practice patterns, 226-32
 profiling
 assessment of provider per-
 formance and, 228-29
 quality improvement and,
 228-32
 utilization review and, 228-
 29
 Preferred provider organizations,
 222, 225, 230 utilization
 review, 225
 Psychoactive drugs
 AIDS prevention programs
 and, 426-42
 relapse, 440-42
 celebratory/prohibition cycle
 of attitudes toward, 443
 harm reduction from, 414,
 424-44
 intravenous administration of
 dependence and, 413
 overdosing and, 413
 tolerance and, 413
 patient restraint via, 558,
 560, 567-68, 576-79
 adverse side effects of, 567
 mentally ill and, 558, 560,
 567-68, 576-79
 Omnibus Budget Reconcili-
 ation Act (OBRA)
 1987 and, 576-79
 regulations regarding, 568,
 576
 related health risks of
 endocarditis, 413, 418
 hepatitis B, 413
 HIV/AIDS, 413-44
 sexual transmission of disease
 and, 415-17, 420, 423,
 441
 (See also Elderly, Intravenous
 drug users, Restraints)
 Public health
 conceptual models in, 479-80
 definition of, 471-78
 health research and, 472-75
 human resource development
 and, 482-83
 leadership, 483-87
 practice of, 477
 researchers and
 decisionmakers in, 483-
 87
 utilization, 483-87
 Public health laboratory
 benefits of national network
 for surveillance
 e.g. antibiotic-resistant *Sal-
 monella enteritidis*,
 652

e.g. hemolytic uremic syn-
 drome from *Es-
 cherichia coli*, 652
 dangers of cutting back
 e.g. measles, 651
 e.g. tuberculosis, 650-51
 financial difficulties of, 657-
 58
 functions of
 assessment, 650-52
 assurance, 654
 policy development, 653-
 54
 future of, 661-62
 health or welfare?, 657
 local, 654-55
 state, 643-46, 654-56
 Q
 Quality of care
 improving
 practice guidelines and,
 232-39
 profiling practice patterns
 and, 228-32
 maintaining
 control of volume of ser-
 vices and, 223-27
 requirements for controlling
 volume while, 226-
 27
 R
 Race
 breast cancer detection and,
 622
 health status and, 355-60
 poverty and, 356-60
 smoking prevalence and
 women of reproductive age
 and, 383
 Radiation
 atomic bomb survivors and,
 77-78, 85-86
 diet and, 74
 dose-response, 74
 high-dose, 173
 Nevada test site, 74
 paternal exposure to
 adverse developmental out-
 comes and, 160, 162-
 63, 168
 behavioral effects in off-
 spring and, 168
 childhood leukemia in off-
 spring and, 172
 increased cancer risk to off-
 spring from, 172-73
 Utah fallout studies, 83-84
 RAND Health Insurance Experi-
 ment, 222
 Random effects models, 56-58,
 61
 Recycling, 141-42, 146-47,
 153-55
 advantages of, 141
 local requirements for, 142
 metals, 147
 paper, 141, 146-47
 technology, 146

Regression analysis
 generalized estimating equa-
 tions and, 51, 60-64
 generalized linear models, 43,
 46, 51-52, 55-58, 66
 inadequacies of, 47-51
 logistic models, 45-46, 53
 marginal models, 55-56
 Markov model, 58-60, 62
 odds ratio, 51, 54-56, 64-65
 random effects models, 56-
 58, 61
 survival analyses, 43
 transition models, 58-60, 62
 unified statistical method, 45,
 55-62
 Regression coefficients, 80
 Reproducibility studies, 73
 Reproductive outcomes (See De-
 velopmental outcomes)
 Resource depletion, 116
 Resource development
 health systems and
 comprehensive, 336, 344-
 47
 entrepreneurial, 336-40
 socialist, 336, 347-51
 welfare-oriented, 336, 340-
 44
 Restraints
 change in US social philoso-
 phy regarding, 545
 chemical
 adverse side effects of,
 567
 mentally ill and, 567-68,
 576-79
 regulations regarding, 568,
 576
 dangers of, 547-48, 557,
 566
 iatrogenic sequelae of, 558
 nursing home elderly and,
 545-81
 patients' rights and, 548
 professional dominance ver-
 sus patient autonomy
 and, 545-46, 548, 558
 proposed regulations regard-
 ing, 549, 560, 568, 576
 quality of life and, 547
 restraint control movement,
 546-49, 557-60
 evidence in support of,
 549, 557-59
 individualized care and,
 580
 responses to, 560
 (See also Elderly; Psychoac-
 tive drugs, patient re-
 straint)
 Retinitis
 progressive
 cytomegalovirus and, 21-
 22
 Risk perception, 183-200
 defining risk and, 190-91
 designing risk communi-
 cations and, 196-200
 perceived lethality and, 189
 perceived invulnerability and,
 189-90

- S
- Safety belts
campaign to increase use of, 525-28
child-restraint systems and, 525
use laws, 519-20
voluntary use of, 519
- Sanitation
public health laboratory and detection of food and water-borne infections and, 652
future of, 649-63
history of, 637-46
- Scabies
epidemiologic synergy with HIV, 35
- Sentinel Events Notification System for Occupational Risks (SENSOR), 212
- Sentinel health events
cluster reports and, 210
databases, 209
decision rules, 210-11
defining, 206-8, 210
changes in pattern and, 207-8
localized clustering of rare events and, 207
single events and, 206-7
occupational exposures and, 208-9
reasoning, 206, 210
sentinel cancers, 208-9
sentinel species, 208
surveillance studies and, 209-10
surveillance technology and, 205, 212, 215
time-series analysis and, 210
Sentinel species, 208
- Seventh-Day Adventists
breast and endometrial cancer rates among, 5-6
- Sewage disposal, 137
- Sex hormone-binding globulin (SHBG)
estrogen bioactivity and, 2-3
vegetarian diet and, 5-8
- Sex steroid hormones
androstenedione aromatization of, 1-3
cancer risk and, 1-14
estradiol, 2-14
estrogens, 1-14
estrone, 2-3
sex hormone-binding globulin and, 2-8
- Sexually transmitted diseases
candidiasis, 33,
chancroid, 30-31, 36, 458-59
chlamydia, 32, 459
cytomegalovirus, 21-22
epidemiologic synergy with HIV, 19-36, 457-59
genital ulcer disease, 30-31, 458-59
gonorrhea, 32, 459
hepatitis B and, 22-24
- herpes simplex type 2, 19-21, 458-59
HIV, 19-36, 415-18, 420, 423, 441, 451-62
intravenous drug users and, 415-18, 420, 423, 441
human papillomavirus infection, 24-26, 459
Kaposi's sarcoma, 33-35
molluscum contagiosum, 26-27
pelvic inflammatory disease, 32-33
scabies, 35
syphilis, 27-30, 458-59
trichomoniasis, 459
vaginitis, 33
vaginosis, 33
- Smoking
California's Proposition 99
against, 586, 590-92, 594-95, 600-3
broad effects of, 600-3
impact on tobacco use of, 594-95
tobacco industry's efforts against, 591-92
cessation of, 592-94, 598-600
culture and, 361, 363-64
high-density lipoprotein cholesterol and, 103
initiation of, 593-94
low serum total cholesterol and, 103
paternal
birth defects and, 171
prenatal exposure to, 381-82
infant respiratory infections and, 382
Sudden Infant Death Syndrome (SIDS) and, 382
prenatal exposure to
abruptio placenta and, 381
bleeding during pregnancy and, 381
intrauterine growth retardation and, 381-82
low birthweight and, 379-82
placenta previa and, 381
spontaneous abortion and, 381
prenatal smoking cessation intervention trials, 388-407
carbon monoxide monitoring in, 397, 404
cotinine used in, 404-5
salivary thiocyanate used in, 399, 404-5
prevalence of, 595-96
prevalence among women of, 382-85
education level and, 383
pregnancy and, 384-85
race and, 383
teenage years and, 383
prevention of, 589-90
trends in, 586-88
California, 586-88
socioeconomic status and, 587
United States, 586-88
- women's smoking behavior, 385-87
addiction and, 386-87
depression and, 386
quitting and, 386-88
stress and, 385-87
weight control and, 386
- Social security, 295, 301, 305
shrinking over-65 labor force and, 295
- Social Security Disability Insurance (SSDI) program, 296
- Socioeconomic status
asthma and, 504-5
cancer and, 358-61
disease incidence and mortality and, 360-61
health knowledge, attitude, and behavior and, 363-66
health promotion and, 360-75
health status and, 356-75
lead exposure and, 365-66
risk factor and exposures and, 361-63
- Solid waste (See Municipal solid waste)
- Soya
possible protective role in breast cancer of, 11
- Space-time clusters
sentinel health events and, 214
- Specific locus test
mammalian germ cell mutagenicity and, 160-62
- Sperm production
male environmental exposures and, 159-60
- Spontaneous abortion
smoking and, 381
- Stroke (See Hemorrhagic stroke)
- Structural equations
exposure measurement and, 81-82
- Sudden cardiac death, 313
- Sudden Infant Death Syndrome (SIDS)
postnatal smoking exposure and, 382
- Supplemental Security Income program, 296
- Surveillance
sentinel health events and, 205-15
decision rules regarding, 210-11
space-time clusters, 214
spatial analysis, 214
studies, 209-10
technology, 205, 212, 215
time-series analysis, 212-13
- Syphilis
epidemiologic synergy with HIV, 27-30
HIV and, 27-30, 458-59
benzathine penicillin G and, 28-29
neuro-, 28-29
prevalence
Africa, 27
United States, 27

Syringe exchange programs
HIV transmission reduction
and, 427, 434-36, 439-40

T

Testosterone, 8

Thiocyanate

salivary, 399, 404

Tobacco tax

California's Proposition 99,
590-95, 600-3

broad effects of, 600-3
impact on tobacco use of,
594-95

Traffic injuries

bicyclists and, 535-37

control of

public health commitment
to, 517

fatal

number of, 515, 520

improvement in fatality rate
from

campaign against drunk

drivers, 521-24

55-mile-per-hour speed
limit and, 516

improved motor vehicle de-
sign and, 517-18

Interstate Highway System
and, 517

lower vehicle occupancy
rate and, 518-19

raising minimum legal
drinking age, 522-23

motorcyclists and, 535-37

pedestrians and, 535-36

Traffic safety policies

cost-effectiveness of, 528-30

Transition models, 58-60, 62

Transportation (See Automobile
safety, Traffic injuries)

Trash (See Municipal solid
waste)

Treponema pallidum, 27-29

HIV infection and, 27-29

benzathine penicillin G
and, 28-29

Trichomoniasis

HIV and, 459

Tuberculosis

HIV-infected drug users and,
418-20

multidrug-resistant, 419

renovation of health care facil-
ities to control, 420

U

Ubiquinone, 106

Ultraviolet radiation

biological effects of, 118-20

cataracts, 119-20

DNA damage, 119

immunosuppression, 19

impaired photosynthesis and,
119

malignant melanoma, 119-
20

microorganisms and, 119

phytoplankton and, 118-

19, 121

skin damage, 119-20

public health action, 121-22

public policy regarding, 122

research needs, 121

Unbundling, 221

Unified statistical method, 45,
55-62

Uninsured

children, 248

indicators of access to care,
247-64

patient characteristics, 246-47

(See also Health insurance ac-
cess, Health services ac-
cess)

United Nations Conference on
Environment and Develop-
ment (UNCED), 128-29

United Nations Environmental
Program (UNEP), 118,
128-29

Report on the Environmental
Effects of Ozone Deple-
tion, 118

Urban growth

municipal solid waste and,
137-42

Utilization

(See Health services access)

Utilization review, 223-24, 228-
32

appropriate care and

practice guidelines and, 232

profiling of practice pat-
terns and, 228-29

V

Vaginal candidiasis

intravenous drug users and,
418, 420

Vaginitis

trichomonal, 33

Vaginosis

bacterial, 33

Validation studies, 73

Vegitarian diet

breast cancer risk and, 5-8
Seventh-Day Adventist
women and, 5-6

Vitamin E

serum total cholesterol and,
103

Vulvovaginal candidiasis, 33

W

Well-being, 469

Wilm's tumor, 172-73, 175

Worldwatch Institute, 115


Y

Yves Biraud Seminars 1979-
1981, 205-6

Z

Zidovudine (AZT)

ganciclovir treatment for cyto-
megalovirus and, 22



CUMULATIVE INDEXES

CONTRIBUTING AUTHORS, VOLUMES 5-14

A

Aldrich, T. E., 14:205-17
 Allan-Andrilla, C. H., 13:31-57
 Allen, D., 9:503-26
 Andrus, J. K., 13:239-52
 Aral, S. O., 14:451-67
 Ashford, N. A., 6:383-401
 Ashley, M. J., 9:233-71
 Auffrey, C., 10:281-97
 Autry, J. H., 7:535-43
 Axelson, O., 12:235-55
 Axnick, N., 11:251-66

B

Baker, D. B., 6:367-81
 Baker, E. L., 9:223-32
 Banton, J., 12:17-40
 Barer, M. L., 12:481-518
 Battista, R. N., 9:21-45
 Bellinger, D., 12:111-41
 Bender, T. R., 11:251-66
 Beresford, S. A. A., 13:469-88
 Bergner, M., 8:191-210;
 11:165-83
 Berghold, L., 12:157-75
 Berkman, L., 5:413-32
 Bernier, R. H., 13:385-98
 Best, J. A., 9:161-201
 Bindman, A. B., 14:219-41
 Bingham, E., 11:419-34
 Blair, S. N., 9:403-25; 13:99-
 126
 Blount, J. H., 6:85-106
 Bor, D. H., 10:363-83
 Bostrom, A., 14:183-203
 Bosworth, K., 8:387-415
 Brennehan, G., 13:269-85
 Breslow, L., 8:289-307; 11:1-
 28; 14:585-604
 Breslow, N., 5:385-411
 Brock, D. B., 8:211-34
 Brody, J. A., 8:211-34
 Brown, B. W. Jr., 5:267-92
 Brown, C., 8:441-67
 Brown, E. R., 11:377-400

Brown, J. L., 9:503-26
 Brown, K. S., 9:161-201
 Brown, S. L., 6:247-67
 Brown, S. T., 11:251-66
 Brownell, K. D., 7:521-33
 Bruce-Chwatt, L. J., 8:75-110
 Buchner, D. M., 13:451-68,
 469-88
 Bunker, J. P., 7:391-409

C

Calabrese, E. J., 6:131-46
 Caldart, C. C., 6:383-401
 Callas, P., 7:441-71
 Canada, A. T., 6:131-46
 Capron, A. M., 7:59-75
 Caskey, C. T., 10:27-48
 Casper, R., 7:535-43
 Caspersen, C. J., 8:253-87
 Castleman, B. I., 8:1-19
 Cayten, C. G., 12:401-24
 Chaffin, D. B., 7:77-104
 Cheadle, A. C., 13:31-57
 Cherkin, D., 12:141-56
 Chewning, B., 8:387-415
 Chiang, C. L., 12:281-307
 Childs, J. E., 13:79-98
 Chin, J., 11:127-42
 Chirikos, T. N., 14:293-312
 Clever, L. H., 9:273-303
 Clough, V. M., 13:151-71
 Colsher, P. L., 10:203-19
 Conn, J. M., 8:417-40
 Connell, F. A., 8:51-74
 Conrad, D., 12:141-56
 Conroy, C., 5:163-92
 Corey, L., 14:19-42
 Crowley, J., 5:385-411
 Cummins, R. O., 14:313-33
 Curran, A. S., 12:85-109
 Cutts, F. T., 13:385-98

D

Dallek, G., 11:377-400
 Damasio, A. R., 10:115-40

Damasio, H., 10:115-40
 Davidson, L. E., 8:417-40
 Davis, D. L., 6:195-221
 Davis, R. M., 13:287-318
 de Macedo, C. G., 13:239-52
 de Quadros, C. A., 13:239-52
 DeFries, G. H., 11:401-18
 DeLong, J. V., 14:137-57
 Des Jarlais, D. C., 14:413-50
 Dey, L. J., 13:31-57
 Deyo, R. A., 12:141-56
 Diehr, P. H., 8:51-74; 13:31-57
 Dowdle, W. R., 14:649-64
 Drury, T. F., 5:83-106
 Dusenbury, L., 14:355-77
 Dworkin, R. B., 6:107-30
 Dwyer, J. T., 12:309-34
 Dwyer, J., 14:69-93

E

Edwards, J., 9:427-50
 Eissa, M., 12:519-41
 Elinson, L., 13:197-221
 Elston, M. A., 8:111-35
 English, C. W., 6:269-94
 Ennever, F. K., 11:69-87
 Enterline, P. E., 12:459-80
 Epstein, A. M., 14:243-70
 Eriksen, M. P., 9:47-70
 Eskenazi, B., 7:441-71
 Evans, R. G., 12:481-518

F

Faden, R. R., 12:335-60
 Farewell, V. T., 7:35-58
 Farfel, M. R., 6:333-60
 Farquhar, J. W., 6:147-93
 Faustman, E. M., 14:159-81
 Fielding, J. E., 5:237-65;
 11:401-18; 12:209-34
 Fine, L. J., 11:89-103
 Fineberg, H. V., 6:1-20
 Fischhoff, B., 14:183-203
 Flora, J. A., 10:181-201
 Floyd, R. L., 14:379-411

678 CONTRIBUTING AUTHORS

Foege, W. H., 11:251-66
Franklin, B. A. K., 13:341-62
Frazier, T. M., 6:419-32
Frenk, J., 14:469-89
Freirichs, R. R., 12:257-80
Freund, D. A., 8:137-63
Fried, L. P., 10:319-32
Friedman, S. R., 14:413-50

G

Gearon, S. A. N., 13:341-62
Gergen, P. J., 14:491-513
German, P. S., 10:319-32
Gerr, F., 12:543-66
Gershney, E. L., 10:299-317
Gibbs, R. A., 10:27-48
Giovino, G., 14:379-411
Glass, G. E., 13:79-98
Gordon, N. F., 13:99-126
Gordon, N. P., 7:127-49
Gostin, L., 13:197-221
Grace, T. W., 13:253-68
Graham, J. D., 14:515-43
Green, L. W., 5:215-36;
11:319-34
Greenberg, R. S., 6:223-45
Greenough, W. B. III, 10:221-44
Greenwald, P., 7:267-91
Grosche, R. N., 10:281-97
Grover, S. A., 9:21-45
Grumbach, K., 11:297-318
Guidotti, T. L., 13:151-71
Gusman, S., 7:293-312
Gustafson, D. H., 8:387-415

H

Hale, W. E., 13:415-30
Hall, J. A., 10:163-80
Halperin, W. E., 6:419-32
Handler, A., 13:269-85
Handsfeld, H. H., 6:85-106;
14:19-42
Hanis, C. L., 11:105-25
Hanley, R. J., 12:67-84
Harley, N. H., 13:127-50
Harris, R. H., 6:269-94
Harrison, R., 7:441-71
Hart, L. G., 8:51-74
Harter, P. J., 7:293-312
Hawkins, R. P., 8:387-415
Henderson, D. A., 11:335-58;
13:239-52
Hertzman, C., 12:481-518
Hertzstein, J., 7:217-35
Higashi, G. I., 9:483-501
Highland, J. H., 6:269-94
Hochberg, M. C., 9:379-401
Hogan, M. D., 8:355-85

Holford, T. R., 12:425-57
Holmes, K. K., 6:85-106;
14:19-42
Holtzman, N. A., 7:237-66
Hopps, H. E., 9:203-21
Hornbrook, M. C., 6:295-324
Hubert, H. B., 7:493-502
Huff, J. E., 8:355-85
Hughes, J. M., 7:171-92
Hunt, A. T., 6:325-32
Hurley, R. E., 8:137-63
Hyman, B. T., 10:115-40

J

Jacobs, D. R., 14:95-114
Jameson, W. J., 11:297-318
Jamison, D. T., 11:335-58
Jernigan, D. H., 10:245-79
Johnson, M., 14:585-604

K

Kane, R. A., 14:545-84
Kane, R. L., 14:545-84
Kaplan, N. M., 7:503-19
Kasl, S. V., 5:319-41
Kass, N. E., 12:335-60
Katzman, R. L., 13:431-49
Kellermann, A. L., 12:17-40
Kelsey, J. L., 9:379-401
Kendrick, J. S., 8:253-87
Kerner, J. F., 14:355-77
Keyserling, W. M., 7:77-104
Khouri, M. J., 7:237-66
Kim-Farley, R., 13:223-37
King, M.-C., 5:1-52
Klein, R. C., 10:299-317
Kleinbaum, D. G., 6:223-45
Kleinman, J. C., 10:423-40
Kleinstein, R. N., 5:369-84
Klerman, G. L., 13:319-39
Kneip, T., 10:1-25
Kohler, L., 12:177-93
Koch, G. G., 9:123-60
Koopsell, T. D., 13:31-57
Kogevinas, M., 8:111-35
Kohl, M. H. W., 13:99-126
Koplan, J. P., 11:267-96
Koskela, K., 6:147-93
Kottke, T. E., 6:147-93
Kramer, P. S., 9:333-59
Kraus, J. F., 5:163-92; 6:403-18; 9:99-121
Kreuter, M. W., 11:319-34
Kristal, A. R., 13:31-57
Kukull, W. A., 13:431-49
Kunins, H., 12:361-82
Kuritz, S. J., 9:123-60

L

Labarthe, D. R., 7:193-215;
12:519-41
LaCroix, A. Z., 13:451-68,
469-88
Landis, J. R., 9:123-60
Landrigan, P. J., 7:337-56;
11:359-75; 12:543-66
Larson, E. B., 8:165-90;
13:431-49, 451-68, 469-88
Lasker, R., 14:219-41
Last, J. M., 14:115-36
Lave, J. R., 5:193-213; 10:141-61
Lave, L. B., 5:193-213; 11:69-87
Lawrence, R. S., 10:363-83
Leaf, A., 7:411-39
Leaning, J., 7:411-39
Leape, L. L., 13:363-83
Leaverton, P., 14:205-17
LeDuc, J. W., 13:79-98
Lee, G. M., 5:1-52
Lee, P. R., 7:217-35; 11:297-318; 14:219-41
Lee, R. K., 12:17-40
LeMaistre, C. A., 9:47-70
Letz, R., 12:543-66
Liang, K.-Y., 14:43-68
Lindsteadt, J. F., 13:341-62
Ling, J. C., 13:341-62
Lioy, P. J., 10:69-84
Lippmann, M., 10:49-67
Lomas, J., 12:41-65
Louis, T. A., 6:1-20
Lovato, C. Y., 13:253-68
Luthy, D. A., 8:165-90
Lyle, J., 13:269-85
Lynch, B. S., 7:267-91
Lyons, B., 9:427-50

M

Maccoby, N., 6:147-93; 10:181-201
Mahler, H., 9:71-97
Maibach, E. W., 10:181-201
Mallino, D. L., 11:359-75
Mandelblatt, J. S., 14:355-77
Mandula, B., 6:195-221
Mann, J. M., 11:127-42
Marmot, M. G., 8:111-35
Marstrand, D., 7:357-89
Martin, D. C., 13:31-57
Mayo, F., 7:357-89
McAlister, A., 6:147-93
McGinnis, J. M., 8:441-67;
11:231-49
McNeil, B. J., 5:135-61
Meade, M. S., 7:313-35

- Meador, W. V., 11:419-34
 Mechanic, D., 12:1-15
 Meisels, S. J., 9:527-50
 Mendeloff, J. M., 12:401-24
 Mercy, J. A., 12:17-40
 Meredith, C. N., 12:309-33
 Mills, S. L., 13:287-318
 Modlin, J., 13:1-30
 Moolgavkar, S. H., 7:151-69
 Morrissey, M. A., 14:271-92
 Morrison, P. R., 6:325-32
 Moses, L. E., 5:267-92; 8:309-53
 Mosher, J. F., 10:245-79
 Mosley, W. H., 11:335-58
 Mosteller, F., 6:1-20
 Muir, C. S., 11:143-63
 Mullen, P. D., 9:305-32; 14:379-411
 Murt, H. A., 5:107-33
- N
- Navarro, V., 8:1-19; 10:85-94
 Needleman, H. L., 12:111-14
 Nelkin, D., 10:95-113
 Nelson, N., 11:29-37
 Nersesian, W. S., 9:361-77
 Newell, G. R., 9:47-70
 Newhouse, J. P., 11:207-30
 Nissinen, A., 6:147-93
 Novotny, T. E., 13:287-318
- O
- O'Hara, N. M., 9:403-25
 Olive, J. M., 13:239-52
 Olshan, A. F., 14:159-81
 Omenn, G. S., 6:107-30; 9:273-303
 Orenstein, W. A., 13:385-98
 Osborn, J. E., 9:551-83
- P
- Paffenbarger, R. S. Jr., 13:99-126
 Pagano, M., 6:325-32
 Parcel, G. S., 9:403-25
 Pades H., 10:403-22
 Parkman, P. D., 9:203-21
 Party, E., 10:299-317
 Pate, R. R., 9:403-25
 Patrick, D. L., 11:165-83; 13:31-57
 Patrick, K., 13:253-68
 Pauker, S. G., 5:135-61
 Pels, R. J., 10:363-83
 Perine, P. L., 6:85-106
 Perrin, E. B., 13:31-57
 Pierce, J. P., 12:383-400
 Pollack, S. H., 11:359-75
- Powell, K. E., 8:253-87
 Prentice, R. L., 7:35-58
 Puska, P., 6:147-93
- Q
- Quadrel, M. J., 14:183-203
 Quinn, T. C., 13:1-30
- R
- Rall, D. P., 8:355-85
 Rankin, J. G., 9:233-71
 Reatig, N., 7:535-43
 Reisine, S. T., 9:1-19
 Renner, C., 10:85-94
 Rhoades, E. R., 13:269-85
 Richmond, J. B., 11:185-205
 Rimer, B. K., 14:379-411
 Rivara, F. P., 13:509-28
 Robbins, F. C., 7:105-25
 Robbins, J. B., 7:105-25
 Robertson, L. S., 7:13-34
 Roemer, M. I., 14:335-53
 Romano, R. A., 13:287-318
 Room, R., 5:293-317
 Rose, D. P., 14:1-17
 Rosenberg, M. L., 8:417-40
 Rosenfield, A., 10:385-401; 12:361-82
 Rosenstock, L., 7:337-56
 Roter, D. L., 10:163-80
 Rothenberg, R. B., 11:267-96
 Rothman, M. L., 8:191-210
 Rowland, D., 9:427-50
 Russ, A., 13:1-30
- S
- Sacco, C., 6:131-46
 Salonen, J. T., 6:147-93
 Santi, S. M., 9:161-201
 Sasco, A. J., 11:143-63
 Sattin, R. W., 13:489-508
 Schaffarzick, R. W., 7:391-409
 Schull, W. J., 11:105-25
 Schweitzer, S. O., 13:399-410
 Schwetz, B. A., 8:355-85
 Scitovsky, A. A., 7:59-75
 Scrimshaw, N. S., 11:53-68
 Shapiro, D. W., 14:219-41
 Sharp, D. S., 7:441-71
 Shiota, S. R., 13:399-410
 Shonick, W., 5:53-81
 Shopland, D., 8:441-67
 Shore, R. E., 13:127-50
 Shy, K. K., 8:165-90
 Siegel, J. M., 5:343-67
 Sigal, L. H., 12:85-109
 Silverman, M. M., 10:403-22
 Simons-Morton, B. G., 9:403-25
- Simopoulos, A. P., 7:475-79, 481-92
 Smith, A. H., 7:441-71
 Smith, E. A., 9:161-201
 Smith, G. S., 9:99-121
 Smith, J. C., 8:417-40
 Sondik, E., 7:267-91
 Sorensen, G., 8:235-51
 Spinner, N. B., 5:1-52
 Starfield, B., 6:21-40
 Stason, W. B., 6:41-63
 Stewart, R. B., 13:415-30
 Stoto, M., 13:59-78
 Stover, E. S., 7:535-43
 Stram, D., 14:69-93
 Sullivan, S. E., 14:379-411
- T
- Taylor, C. E., 10:221-44
 Taylor, V., 14:605-33
 Tenforde, T. S., 13:173-96
 Tennant, R. W., 8:355-85
 Terris, M., 11:39-51
 Thomas, D. C., 9:451-82
 Thomas, D., 14:69-93
 Thompson, P. D., 8:253-87
 Thomson, G., 5:1-52
 Thomson, S. J., 9:161-201
 Toniolo, P., 10:1-25
 Torrens, P. R., 6:65-83
 Tuomilehto, J., 6:147-93
- U
- Upton, A. C., 10:1-25; 13:127-50
 Urban, N., 14:605-33
- V
- Valderrri, R. O., 14:635-48
 Van Hoesen, G. W., 10:115-40
 Vanderpool, N. A., 11:185-205
 Varas, C., 12:519-41
 Verbrugge, L. M., 8:235-51; 10:333-61
 Vladeck, B. C., 9:333-59
 Volinn, E., 12:141-56
- W
- Wagener, D. K., 14:491-513
 Wagner, E. H., 13:31-57, 451-68, 469-88
 Wald, A., 14:19-42
 Wallace, R. B., 10:203-19
 Waller, J. A., 8:21-49
 Walsh, D. C., 7:127-49; 13:197-221
 Ward, T. P., 14:413-50
 Warner, K. E., 5:107-33

680 CONTRIBUTING AUTHORS

Weeks, J. L., 12:195-207
 Wegman, D. H., 6:363-65;
 11:89-103
 Weill, H., 7:171-92
 Weinstein, M. C., 6:41-63
 Weiss, K. B., 14:491-513
 Weissman, J. S., 14:243-70
 Weissman, M. M., 13:319-39
 West, A., 10:403-22

White, E., 14:605-33
 Wiener, J. M., 12:67-84
 Wilkerson, A., 10:299-317
 Williams, C. C., 14:545-84
 Williams, T. F., 8:211-34;
 14:545-84
 Wilson, R. W., 5:83-106
 Wingard, D. L., 5:433-58
 Wolf, M. E., 13:509-28

Wolman, A., 7:1-12
 Wood, M., 7:357-89
 Woolson, R. F., 10:423-40
 Wensch, M. R., 5:1-52

Z

Zeger, S. L., 14:43-68

